Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

J Infect Dis. 2022 Sep 28;226(7):1195-1199. doi: 10.1093/infdis/jiac190.

Abstract

For head-to-head comparison of human papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old vaccine-naive women were given either the bivalent (n = 188) or the nonavalent HPV vaccine (n = 184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured. Antibodies against HPV16/18 were higher after bivalent HPV vaccination (mean international units [IU] 1140.1 and 170.5 for HPV16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the nonvaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.

Keywords: antibody; bivalent; human papillomavirus; international units; nonavalent; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alphapapillomavirus*
  • Antibodies, Viral
  • Antibody Formation
  • Female
  • Human papillomavirus 16
  • Human papillomavirus 18
  • Humans
  • Papillomaviridae
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • Uterine Cervical Neoplasms*
  • Vaccines, Combined

Substances

  • Antibodies, Viral
  • Papillomavirus Vaccines
  • Vaccines, Combined